Episode 3: Performance and Clinical Utility

Part 1 and 2 of this series covers an introduction into the topic of paediatric tuberculosis (TB) and an exploration of TB diagnostics. To round it off, the third podcast addresses the clinical utility of immune response testing in the management of paediatric TB. Various performance characteristics of the QuantiFERON^®-TB Gold Plus (QIAGEN GmbH, Hilden, Germany) assay are shared, including clinical sensitivity compared with bacteriologically-confirmed active TB cases. Finally, the performance of QuantiFERON^®-TB Gold Plus in children aged <5 years and 2 years, as well as in immunocompromised children, is highlighted.

The publication of these podcasts was funded by QIAGEN.